Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 481 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in... August 22, 2024 Ivosidenib with Chemotherapy New Option for Some People with AML May 13, 2022 Woman Battles Breast Cancer While Pregnant, Delivers Healthy Baby Boy October 27, 2020 FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma September 8, 2023 Load more HOT NEWS Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... Doctors Say Girl Has ‘Vanishing Bones’ That Are Slowly Disappearing From... Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma Aiming to Prevent New Cancer Cases, ESMO Calls for Increased Minimum...
